Bionyra Pharma emerged from stealth after raising $165 million in an oversubscribed Series A to develop next-generation biologics for severe immunological and inflammatory diseases. The funding was co-led by Jeito Capital and Sofinnova Partners with participation from Sanofi Ventures, Arkin Bio, and others. The company’s co-founder and CEO, Frédéric Marrache, MD, PhD, is positioning Bionyra around differentiated target and pathway selection for immune-driven conditions. Board appointments include key investors such as Mehdi Ainouche (Jeito) and Anta Gkelou (Sofinnova), alongside representatives from participating backers. For biotech investors, the launch underscores continued appetite for immune-inflammation platforms that can move quickly into clinical development with clear differentiation. For pharma, a new well-capitalized startup increases competitive pressure in the biologics pipeline space focused on inflammatory disease biology.